2016-11-11T13:32:10-06:00 2015-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2015-01-01 943384500 PATH DRUG SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA D POLIUS CHIEF FINANCIAL OFFICER 2062853500 2016-11-11 1 3019519090 2015 2017-02-10 21:41:12Z OLIVIA D POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 7143163 0 X WWW.PATH.ORG X 2000 CA SEE PART III, LINE 1. 8 3 0 0 0 0 5259668 7126779 0 0 10438 12936 0 0 5270106 7139715 6406305 4768944 0 0 0 0 0 0 0 4353184 1228767 10759489 5997711 -5489383 1142004 37978413 14847024 1584692 1605303 36393721 13241721 X PATH DRUG SOLUTIONS (PDS) DEVELOPS AND ADVANCES SAFE AND EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF DISEASES DISPROPORTIONATELY AFFECTING WOMEN AND CHILDREN IN LOW-RESOURCE SETTINGS. WE WORK WITH A VARIETY OF PUBLIC- AND PRIVATE-SECTOR STAKEHOLDERS TO BUILD CROSS-SECTOR COLLABORATIONS, SECURE INTELLECTUAL PROPERTY, REVISIT PROMISING DRUGS OR DRUG CANDIDATES THAT HAVE BEEN SET ASIDE FOR NONMEDICAL REASONS (E.G., BECAUSE OF LACK OF EARNING POTENTIAL), AND HARNESS SCIENTIFIC AND MANUFACTURING CAPACITY IN HIGH- AND LOW- OR MIDDLE-INCOME COUNTRIES TO ENSURE DRUGS ARE AVAILABLE AND ACCESSIBLE TO ALL THOSE WHO NEED THEM. 0 0 5004556 4270566 WORKING THROUGH CROSS-SECTOR PARTNERSHIPS, PDS ADVANCED DRUG RESEARCH AND DEVELOPMENT TO COMBAT TOP GLOBAL HEALTH THREATS TO WOMEN AND CHILDREN IN 2015. PRODUCT DEVELOPMENT: WORK TO STOP MALARIA CONTINUED WITH SHIPMENT OF 51 MILLION ANTIMALARIAL TREATMENTS MADE USING SEMISYNTHETIC ARTEMISININ (SSART) TO MORE THAN 20 COUNTRIES ACROSS SUB-SAHARAN AFRICA. SSART-WHICH WAS DEVELOPED AND SCALED UP BY A GLOBAL PARTNERSHIP INVOLVING PDS-COMPLEMENTS THE BOTANICAL SUPPLY OF ARTEMISININ, HELPING TO STRENGTHEN THE SUPPLY CHAIN FOR ANTIMALARIAL TREATMENTS AND STABILIZE PRICING. ALSO, THE AVAILABILITY OF SSART INCREASES ACCESS TO TREATMENT FOR THE MILLIONS SICKENED BY MALARIA EVERY YEAR, OFTEN YOUNG CHILDREN IN AFRICA. WE ALSO PARTNERED WITH THE CLINTON HEALTH ACCESS INITIATIVE TO FURTHER STABILIZE ARTEMISININ MARKETS BY DEVELOPING PROJECTIONS FOR FUTURE SUPPLY AND DEMAND. THIS WORK INCLUDED ASSESSING THE RATIONALE FOR AN SSART RESERVE AND ESTIMATING THE AMOUNT THAT WOULD BE NEEDED FOR SUCH AN ENDEAVOR. WITH OUR GLOBAL PARTNERS, WE ALSO ADVANCED A LONG-ACTING INJECTABLE FORMULATION OF RILPIVIRINE, TMC278 LA, TO A PHASE 2 STUDY. THE PURPOSE OF THE STUDY WAS TO TEST THE SAFETY AND ACCEPTABILITY OF TMC278 LA FOR PREEXPOSURE PROPHYLAXIS (PREP). PREP IS A STRATEGY THAT INVOLVES USE OF ANTIRETROVIRAL MEDICATIONS TO REDUCE THE RISK OF HIV INFECTION IN HEALTHY, UNINFECTED ADULTS. CLINICAL TRIALS HAVE SHOWN THAT DAILY, ORAL PREP USING THE ANTIRETROVIRAL DRUGS TENOFOVIR AND EMTRICITABINE DRAMATICALLY REDUCES THE RISK OF HIV INFECTION FOR MEN AND WOMEN WHO TAKE IT AS DIRECTED. A LONG-ACTING FORMULATION OF PREP THAT REQUIRES LESS-FREQUENT DOSING HAS THE POTENTIAL TO IMPROVE UPTAKE AND ADHERENCE. IT WOULD ALSO EXPAND THE GLOBAL TOOLBOX OF PREVENTION INTERVENTIONS, PROVIDING SAFE AND EFFECTIVE CHOICES TO ADDRESS DIFFERENT CIRCUMSTANCES AND PREFERENCES. IN ADDITION, PDS WORKED IN 2015 TO ADVANCE THE DEVELOPMENT OF THERAPEUTICS TO BETTER ADDRESS DIARRHEAL DISEASE, A LEADING CAUSE OF ILLNESS AND DEATH AMONG YOUNG CHILDREN IN LOW-RESOURCE SETTINGS. PDS COLLABORATED WITH PARTNERS AT ERASMUS UNIVERSITY TO EVALUATE THE POTENTIAL EFFICACY OF DIARRHEAL DISEASE DRUG CANDIDATES USING HUMAN INTESTINAL BIOPSY TISSUE. APPROVAL FOR THESE STUDIES WAS OBTAINED FROM THE ERASMUS UNIVERSITY MEDICAL CENTER'S MEDICAL AND ETHICAL REVIEW COMMITTEE. 788229 498378 INTERNATIONAL DEVELOPMENT: TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED IN 2015 TO FURTHER DEVELOP AND DESIGN A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT.IN ADDITION, PDS ADVANCED WORK ON THE ADOPTION OF PAROMOMYCIN INTRAMUSCULAR INJECTION (PMIM) BY THE GOVERNMENTS OF BANGLADESH AND NEPAL FOR THE TREATMENT OF VISCERAL LEISHMANIASIS (VL), ALSO KNOWN AS KALA-AZAR, WHICH IS A NEGLECTED INFECTIOUS DISEASE THAT AFFECTS TENS OF THOUSANDS EACH YEAR. PMIM IS AN EFFECTIVE AND SAFE TREATMENT FOR THE DISEASE AND HAS SOME ADVANTAGES OVER OTHER THERAPIES. MOREOVER, PDS BUILT CAPACITY WITHIN BANGLADESH AND NEPAL TO CARRY OUT FOCUSED PHARMACOVIGILANCE STUDIES FOR DRUGS USED IN VL AND POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL) TO ENSURE THEIR SAFETY. PDS ALSO CONDUCTED A STUDY ON THE FREQUENCY OF PKDL AMONG VL PATIENTS TREATED WITH MONOTHERAPY OR COMBINATION THERAPY IN BANGLADESH TO DETERMINE WHICH TREATMENT BEST PREVENTS SUBSEQUENT ILLNESS. 5792785 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 IN 0 0 0 0 0 0 0 0 X 8 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 CA WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS PRESIDENT & CEO 1.00 39.00 X X 0 607729 59038 OLIVIA D POLIUS TREASURER & CFO 1.00 39.00 X X 0 264997 46727 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 268812 39328 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 316540 58018 JORGE FLORES DIRECTOR 1.00 39.00 X 0 243396 36507 KEITH CHIRGWIN DIRECTOR 2.00 0.00 X 0 0 0 KEN DUNCAN DIRECTOR 2.00 0.00 X 0 0 0 DAN HARTMAN DIRECTOR 2.00 0.00 X 0 0 0 0 1701474 239618 0 0 1 0 0 816360 6310419 7126779 16384 16384 3448 -3448 -3448 -3448 7139715 0 0 12936 4621920 4621920 147024 147024 4504 4504 124777 112777 12000 1789 1789 54615 54471 144 3207 3207 182552 182552 368381 368381 57763 57763 6706 6706 8925 7249 1676 SUBCONTRACTS 389069 389069 EQUIPMENT R&M 16643 16345 298 LAB SUPPLIES 5713 5713 OFFSITE STORAGE 3018 1468 1550 1105 1105 5997711 5792785 204926 0 51703 49655 25840796 12733112 12038366 2045216 707 1933 21081 3352 103127 93107 21856 10020 3904 3736 37978413 14847024 1584692 1605303 1584692 1605303 X 624363 644392 35769358 12597329 36393721 13241721 37978413 14847024 X 1142004 -169 -24293835 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 5997711 0 1 5997711 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 103127 93107 10020 10020 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 6141 EUROPE 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 188556 SOUTH ASIA 0 1 PROGRAM SERVICES PRODUCT DEVELOPMENT 780 SOUTH ASIA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 276841 SOUTH ASIA 0 0 GRANTMAKING 147024 0 1 0 0 0 1 619342 0 619342 SOUTH ASIA INTERNATIONAL DEVELOPMENT 12214 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 49599 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 85211 CHECK/WIRE 3 0 1 0 0 0 0 0 PART I, LINE 2: SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE PROGRAMMATIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 ST LOUIS UNIVERSITY 3700 WEST PINE MALL SUITE 357 ST LOUIS MO 63108 430654872 501(C)(3) 253110 PRODUCT DEVELOPMENT YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 45692 PRODUCT DEVELOPMENT PATH 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 3835141 GENERAL SUPPORT CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE SUITE 400 BOSTON MA 02127 271414646 501(C)(3) 487953 PRODUCT DEVELOPMENT 4 0 PART I, LINE 2: SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE PROGRAMMATIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS PRESIDENT & CEO 0 458417 0 147592 0 1720 0 31000 0 28038 0 666767 0 0 OLIVIA D POLIUS TREASURER & CFO 0 263202 0 0 0 1795 0 31000 0 15727 0 311724 0 0 DANIEL LASTER SECRETARY 0 267092 0 0 0 1720 0 31000 0 8328 0 308140 0 0 DAVID C KASLOW DIRECTOR 0 314890 0 0 0 1650 0 31000 0 27018 0 374558 0 0 JORGE FLORES DIRECTOR 0 243396 0 0 0 0 0 28947 0 7560 0 279903 0 0 PART I, LINE 3 PDS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING METHODS TO ESTABLISH COMPENSATION: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM (GELMAN, ROSENBERG & FREEDMAN) USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PATH'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED AND FILED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PDS HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF ABOVE A DESIGNATED LEVEL IN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND, IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. FORM 990, PART VI, SECTION C, LINE 19 PDS MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: FROM TIME TO TIME, UNSPENT AWARD FUNDS (OR UNUSED OBLIGATIONS) MAY BE RETURNED TO A FUNDER FOR A VARIETY OF REASONS INCLUDING, BUT NOT LIMITED TO, EARLY TERMINATION OF A PROJECT BY A FUNDER, OR A REDUCTION IN FUNDS REQUIRED TO ACCOMPLISH A PROJECT'S SCOPE OF WORK. -24,293,835. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 11A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0